The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases

Inclusion Criteria: * Patients with non-resectable, non-ablatable liver metastases from colorectal adenocarcinoma. * Male or female 18 years or above. * Primary tumour removed with an R0 resection, and histologically verified adenocarcinoma from colon or rectum * Liver metastases measurable by MRI or CT according to RECIST version 1.1 Imaging within 4 weeks prior to inclusion. * No signs of extrahepatic metastatic disease or local recurrence according to MRI and CT of thorax/abdomen and whole body Positron-emission tomography (PET)/ computed tomography (CT) scan. * A colonoscopy performed within the last 12 months in order to exclude multifocal colorectal cancer (CRC) tumours. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Satisfactory blood tests: Hb ≥ 90 g/L (transfusions are permitted to achieve baseline hemoglobin level), White blood cell Count (WBC) \>3,0x109/L, Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L, platelet Count (PLT) \>75, Bilirubin\<2 x upper normal level, Aspartate aminotransferase (ASAT), Alanine aminotransferase (ALAT)\<5 x upper normal level, Calculated Creatinine clearance ≥ 50 mL/min(MDRD). * Received at least 2 months of chemotherapy with no signs of progressive disease according to RECIST-criteria at the last evaluation before randomization. * One year or more from the initial CRC diagnosis to the date of inclusion in the study * Patient accepted for transplantation by a national study board * Signed and dated written …